Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Wyeth is now a wholly owned subsidiary of Pfizer16 enrolled

Overview

To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Alzheimer's Disease

Interventions

SRA-333DRUG

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of probable AD according to the NINCDS-ADRDA criteria. * Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive. * Able to give informed consent. Patient's caregiver must consent to participate in the study. Exclusion Criteria: * Significant neurologic disease other than AD that may affect cognition. * Current clinically significant systemic illness which is likely to deteriorate or affect the subject's safety during the study. Other exclusions apply

Locations (3)

Unnamed facility

Phoenix, Arizona, United States

Unnamed facility

Fort Lauderdale, Florida, United States

Unnamed facility

Miami, Florida, United States

Outcomes

Primary Outcomes

To determine the safety and tolerability of multiple ascending fixed oral dose in subject with mild to moderate Alzheimer's Disease

Secondary Outcomes

To assess the pharmacokinetics and pharmacodynamics of multiple ascending fixed dose.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.